• Skip to main content
BC

biochimica clinica

en_US English
en_US English it_IT Italian
  • Home
  • Casi clinici
  • Ahead of print e Ultimo Fascicolo - Accedi per visualizzare gli articoli
  • Archivio BC fino a 2024
  • Sottometti un articolo
  • Norme Autori
  • Cerca

OPINIONI - Opinions

Volume:

Biochimica Clinica 2015; 39(6) 617-626

Pubblicato on-line:

DOI:

Scarica in PDF:

La diagnostica di laboratorio della malattia renale cronica in Italia: armonizzare è d’obbligo

AUTORI

Maria Stella Graziani1, Sandra Secchiero2, Alessandro Terreni3, Anna Caldini3, Mauro Panteghini4
1Azienda Ospedaliera Universitaria Integrata di Verona
2Centro di Ricerca Biomedica, UOC Medicina di Laboratorio, Azienda Ospedaliera-Università di Padova
3Laboratorio Generale, Azienda Ospedaliero-Universitaria Careggi, Firenze
4Dipartimento di Scienze Biomediche e Cliniche ‘Luigi Sacco’, Università degli Studi, Milano

ABSTRACT

The laboratory role in chronic kidney disease (CKD) in Italy: need of harmonization

The diagnosis and classification of CKD are based on laboratory tests. Aim of this paper is to examine different aspects of the laboratory contribution to verify their harmonization at national level. We review relationships between laboratory and clinical organizations, the role of 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines, the quality of creatinine and urine albumin measurements, the status of estimated glomerular filtration rate (eGFR) reporting, the use of cystatin C and testing plans. Questionnaires examining different aspects of the CKD diagnostics were sent out and EQAS for creatinine and urine albumin measurements were carried out. For creatinine measurement, enzymatic assays show the best performance, while for urine albumin a bias still exists between different methods. The eGFR is routinely reported by 75% of surveyed laboratories, but only 15% of them use the equation derived by the CKDEpidemiology Collaboration (CKD-EPI) study. For urine albumin, the recommended first morning void sample is used by ~60% of laboratories, but the wrong terminology of “microalbuminuria” is still used by >40% of them. Cystatin C is offered by a minority of laboratories. In conclusion, even if an improvement can be observed during the recent years, efforts for a better alignment to international recommendations are needed. Often they just require cultural and organizational changes, without the availability of additional economic resources.

BIBLIOGRAFIA

HOME
PRIVACY POLICY
5x1000 Docemus

LOGO SIBioC

EDITORE RESPONSABILE
Alberto Oliaro

EDITORIAL SECRETARY
Edizioni Minerva Medica S.p.A.
Corso Bramante 83-85, 10126 Torino
T +39 011 678282
journals.dept@minervamedica.it

Designed by Biomedia srl
© 2025 SIBioC
P. IVA IT 06484860967